Successfull implementation of the NanoFlowSizer for COVID19 vaccine development
The NanoFlowSizer is now used for the measurement of the particle size of vaccine delivery systems during production, with successful results!
Some of the challenges to creating RNA vaccines is making sure that the RNA gets into the right immune cells and produces enough of the encoded protein. Additionally, the vaccine must stimulate a strong enough response that the immune system can wipe out the relevant bacteria, viruses, or cancer cells when they are subsequently encountered.
Vaccine delivery systems
One of the ways to improve the efficiency of the RNA vaccines is by the use of a suitable delivery system. Therefore, there is an urgent need for the development of new and improved vaccine delivery systems. The most common deliver systems for RNA vaccines for increasing potency include liposomes and cationic polymers. Based on innovations, now a new series of lipid nanoparticles to deliver such vaccines have been developed, being the most clinically advanced non-viral gene delivery system.
Vaccine developers have to optimize nanoformulations for the efficient packaging and safe delivery of the genetic material.
Lipid nanoparticle technology
Lipid nanoparticle formulations of small molecule drugs represent a relatively mature technology. The design of features such as optimal particle sizes (100 nm diameter or less) is required for lipid-based delivery systems. For this reason it is important to have a system that can monitor the particle size during the production of these vaccine delivery systems.